Donor immune cells treatment for recurrent glioblastoma
Part of Cancer clinical trials.
This trial tests a new kind of cell therapy called CAR-T, made from donor cells, to treat glioblastoma that has come back. The treatment targets a specific marker on the tumor (B7H3) and is injected into the brain to attack the cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a glioblastoma brain tumor that has returned or progressed after standard treatment.
- Your tumor tissue shows a specific protein marker called B7H3 (a simple test on a sample).
- You are generally well enough to care for yourself (a score of 60 or higher on the Karnofsky scale).
- You have not had CAR-T therapy before and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This Phase 1 study tests a personalized immune-cell treatment (CAR-T) made from your own cells to attack a marker called B7-H3 on recurring glioblastoma. It may help shrink or control the tumor, but the main goal is to check safety and how the treatment works.
This trial tests a new treatment called CAR-T cell therapy for people whose glioblastoma (a type of brain tumor) has come back or not responded to standard care. The treatment uses your own immune cells (T cells) that are specially modified to attack tumor cells that show a marker called CD276.
This trial tests a new CAR-T cell treatment (SNC-109) for people with glioblastoma that has come back after initial treatment. The therapy uses your own immune cells, modified in a lab, to try to attack the tumor.
This trial tests a new cell therapy (P134 cells) for people whose glioblastoma has come back after standard treatments like radiation or chemotherapy. The therapy uses a patient's own immune cells (PBMCs) to target cancer cells that have specific markers (CD44 or CD133). It also requires a small procedure to place a reservoir under the scalp for drug delivery.
This trial tests a new CAR-T cell therapy for people recently diagnosed with glioblastoma, a type of brain cancer. It uses the patient's own immune cells, modified to target markers on the tumor. The goal is to see if this treatment can help control the cancer after surgery and before standard therapies like radiation or chemotherapy.
Hear when a new Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.